PMID- 25658140
OWN - NLM
STAT- MEDLINE
DCOM- 20150921
LR  - 20151119
IS  - 1424-3997 (Electronic)
IS  - 0036-7672 (Linking)
VI  - 145
DP  - 2015
TI  - The role of rituximab in the treatment of ANCA-associated vasculitides (AAV).
PG  - w14103
LID - 10.4414/smw.2015.14103 [doi]
AB  - The antineutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV) are 
      a group of primary vasculitides that affect predominantly small- to medium-sized 
      blood vessels. AAV include granulomatosis with polyangiitis (GPA), microscopic 
      polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). 
      Disease severity is dictated by the location and extent of the blood vessels 
      affected. If left untreated, systemic forms of AAV are often fatal. The advent of 
      immunosuppressive therapy (cyclophosphamide plus glucocorticoids) has 
      revolutionised the prognosis for patients with AAV, transforming the course of 
      the disease from fatal to one that can be managed, though not without significant 
      treatment-related toxicity. Recently, the monoclonal antibody rituximab was 
      approved for the treatment of GPA and MPA, providing the first major alternative 
      to cyclophosphamide for induction therapy of AAV. This review explores the 
      emerging role of rituximab in the management of this complex disorder.
FAU - Daikeler, Thomas
AU  - Daikeler T
AD  - Rheumatology, University Hospital Basel, Switzerland.
FAU - Kistler, Andreas D
AU  - Kistler AD
AD  - Division of Nephrology, University Hospital, Zurich, Switzerland.
FAU - Martin, Pierre-Yves
AU  - Martin PY
AD  - Nephrology Division, University Hospital and School of Medicine, Geneva, 
      Switzerland.
FAU - Vogt, Bruno
AU  - Vogt B
AD  - Department of Nephrology and Hypertension, Inselspital, University of Bern 
      Medical School, Switzerland.
FAU - Huynh-Do, Uyen
AU  - Huynh-Do U
AD  - Department of Nephrology and Hypertension, Inselspital, University of Bern 
      Medical School, Switzerland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150206
PL  - Switzerland
TA  - Swiss Med Wkly
JT  - Swiss medical weekly
JID - 100970884
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Immunosuppressive Agents)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - IM
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug therapy
MH  - Antibodies, Monoclonal, Murine-Derived/*therapeutic use
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Remission Induction/methods
MH  - Rituximab
EDAT- 2015/02/07 06:00
MHDA- 2015/09/22 06:00
CRDT- 2015/02/07 06:00
PHST- 2015/02/07 06:00 [entrez]
PHST- 2015/02/07 06:00 [pubmed]
PHST- 2015/09/22 06:00 [medline]
AID - smw-14103 [pii]
AID - 10.4414/smw.2015.14103 [doi]
PST - epublish
SO  - Swiss Med Wkly. 2015 Feb 6;145:w14103. doi: 10.4414/smw.2015.14103. eCollection 
      2015.